Hereditary angioedema (HAE) is a rare condition and listed in China’s official National Rare Disease List, issued in 2018. On 7 December, a new option for the autosomal dominant genetic disease was approved in the country in the form of Takeda Pharmaceutical Co. Ltd.'s Takhzyro (lanadelumab).
In HAE, also designated as a rare disease in Europe and the US, nearly half of patients develop upper respiratory tract mucosal edema, which leads to life-threatening suffocation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?